Ropeginterferon Alfa 2b Plus Ruxolitinib for Myelofibrosis

Summary

In this open-label single arm phase 2 study, approximately 20 patients with MF demonstrating suboptimal response to ruxolitinib monotherapy will be enrolled. Patients will continue to receive ruxolitinib at a stable dose and ropeginterferon alfa 2b will be added to the regimen.

Timeline

Start

2025-03-01

Primary completion

2026-12

Completion

2027-12

Drugs

Indications